Certificate of compliance

RELIS - Regionalt legemiddelinformasjonssenter

is in compliance with the HONcode

Logo certificat HONCode
14 Years

Certificate validity: 25 Mar 2015 - Mar 2016

www.relis.no Visit website

Logo certificat HONCode
HONcode identification number:

HONConduct885976

Date of initial review:

04 Jun 2000

Certificate validity:

25 Mar 2015 - Mar 2016

Date of last visit:

18 Sep 2017
See the HONcode seal on the site

Content identified by the HONcode team

The content below is a sample of the content identified at a specific date by the HONcode team that justifies the respect of the eight ethical principles.

RELIS – regionale legemiddelinformasjonssentre – er etablert for å bidra til rasjonell og riktig legemiddelbruk gjennom produsentuavhengig legemiddelinformasjon til helsepersonell. Faglig forsvarlig og riktig bruk av legemidler er et sentralt tema i norsk legemiddelpolitikk.
 

(21 Jul 2016) - Link

This principle is not applicable to this site 

The data displayed correspond to only one of the selected samples.

Referanser
Nasjonal kompetansetjeneste for funksjonelle mage-tarmsykdommer. www.helse-bergen.no/no/OmOss/Avdelinger/mage-tarmsykdommer/Documents/brosjyren.pdf Søkt 27.04.2016.
Norsk legemiddelhåndbok for helsepersonell. Irritabel tarmsyndrom. Linaklotid (constella). www.legemiddelhandboka.no/. Søkt 27.04.2016.
Statens legemiddelverk. Preparatomtale. Linaklotid(constella). Prukaloprid (resolor). www.legemiddelverket.no/legemiddelsok. Søkt 27.04.2016.
Norsk legemiddelhåndbok for helsepersonell. Prokaloprid (resolor). www.legemiddelhandboka.no/. Søkt 27.04.2016.
British Medical Journal.Clinical evidence. Effects of medications; prucalopride. clinicalevidence.bmj.com/x/systematic-review/0413/intervention/sr-0413-i1272284036240.html. Søkt 24.02.2016.
H Dabiree. Central 5-HTa-receptors in blood pressure regulation. Therapie 46 (6): 421–9. PMID.1819150.
S Hegde, R Eglen et al. Peripheral 5-HT4 receptors. FASEB journal 10 (12): 1398–407. PMID 8903510.
N Schanen, S Scherer et al. (1996). Assignment of the 5-hydroxytryptamine (serotonin) receptor 5A gene (HTR5A) to human chromosome band 7q36. 1. Cytogenetic and Genome Research, 72 (2 3), 187–188.
M King, C Marsden et al. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends in Pharmacolgical Sciences. 29 (9): 482–92. PMID19086256.
P Hedlund, J Sutclifffe. Functional molecular and pharmacological advances in 5-HT7 receptor research. Trends Pharmacol. Sci. 25 (9): 481–6. PMID 15559250.
V Naumenko, N Popova et al. Interplay between serotonin 5-HT1A and 5-HT7 Receptors in Depressive Disorders. CNS Neurosci Ther. 20 (7): 582–90. PMID 24935787.
J Tack, M Camilleri et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Alimentary Pharmacology & Therapeutics, 35 (7), 745–767.
Statens legemiddelverk. Cisaprid og domperidonrisko for alvorlige hjertebivirkninger. www.legemiddelverket.no/Nyheter/Bivirkninger/Sider/Cisaprid-og-domperidon---risiko-for-alvorlige-hjertebivirkninger.aspx Søkt 24.02.2016.
J H De Maeyer, R A Lefebre, et al. (2008). 5.HTv receptor agonists: similar but not the same. Neurogastroenterology & Motility, 20 (2) 99– 112.
M R Briejer, J P Bosmans et al. (2001). The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. European journal of pharmacology, 423 (1), 71–83.
J Spencer, J Brown et al. (2004). Modulation of hippocampal excitability by 5-HT 4 receptor agonists persists in a transgenic model of Alzheimer’s disease. Neuroscience, 129 (1), 49–54.
C Carnovale, P Pellegrino et al. (2013). Neurological and psychiatric adverse events with prucalopride: case report and possible mechanisms. Journal of clinical pharmacy and therapeutics, 38 (6), 524–525.
 

(21 Jul 2016) - Link

Publisert: 29.06.2016
 

(21 Jul 2016) - Link

This principle is not applicable to this site 

Pressekontakt: Helle Tjønn Lindland – 23 07 54 42
Ledergruppen RELIS:
Tekniske henvendelser:
 

(21 Jul 2016) - Link

Offentlig finansiering og organisering
RELIS finansieres ved tilskudd fra Helse- og omsorgsdepartementet (HOD). Tilskuddsforvalter er Statens legemiddelverk. Virksomheten styres gjennom årlige oppdragsbrev. De fire RELIS-sentrene har hver sin leder som utgjør RELIS sin ledergruppe.
 

(21 Jul 2016) - Link

is Norwegian Medicines Agency. Operations are run through annual letter of assignment. We have no advertising on our websites and collects nor consequently statistics for use against advertising providers or advertising placement.
By using this inquiry form on "Ask a question" link is necessary to provide personal information on the mantle. The reason is that we must be able to get in touch with whoever asks. In addition used some of the information in statistics such as occupation and place. This information is written to a sheltered area data, only available for RELIS.
We note that this inquiry form is not sent over an encrypted network. Sensitive, identifiable personal information must not be entered.
All personal information about patients and questions quieter, including medical information, data information, e-mail and other contact information will be used exclusively by RELIS and will not be disclosed to any third party.
 

The content of this certificate has been collected by the HON Foundation and may not be used without HON's express consent.

responsive devices

The HONcode's significance

The Health On the Net (HON) certificate guarantees that this website complies with the eight principles of the HON Foundation's Code of Conduct at the date indicated above. The persons responsible for the site commit to maintaining its compliance with the HONcode principles for the duration of the site’s certification.

However, despite the complaint system that has been put in place and the periodic review and automatic monitoring of certified sites to ensure maximum compliance with the HONcode ethical principles, it is impossible to eliminate all risks of incoherence that may appear.

Under no circumstances shall the HON Foundation and/or its partner(s) be held liable for any damages resulting from the use or the inability to use HONcode-certified websites. Similarly, the HON Foundation and/or its partner(s) shall not be held liable for the content of such certified websites or any other website accessible via a hypertext link or through third-party information.

Those responsible for the certified website are responsible for the content of the website unless otherwise provided by law.

More information about the HONcode?
responsive devices

Health website editors

Do you have your own website?

Request HONcode certification!

HONcode certification request

Health information you can trust!

Search HONcode-certified websites:

 

Download the free HONcode toolbar
barre d'outils HONcode

The HONcode toolbar is easy to download and add to your Web browser. It connects in real time to the HON server to verify the certification status of health and medical websites. It does not collect any personal information and contains no spyware or other hidden functions.

Download

Video about the HONcode

YouTube channel

Providing you with trustworthy health information

YouTube channel